A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Pénélope Desroys du RoureLajoie LaurieAude MallavialleLindsay B AlcarazHanane MansouriLise FenouVéronique GaramboisLucie RubioTimothée DavidLoïs CoënonFlorence BoissièreMarie-Christine ChateauGiang NgoMarta JarlierMartín VillalbaPierre MartineauValérie Laurent-MathaPascal RogerSéverine GuiuThierry ChardèsLaurent GrosEmmanuelle Liaudet-CoopmanPublished in: Journal for immunotherapy of cancer (2024)
is a promising immunotherapy for TNBC that could be combined with conventional regimens, including chemotherapy or antiandrogens.